Does Wegovy Affect the Liver — and What Does the Evidence Actually Show?

The common misconception: that these medicines stress the liver

A lot of people assume that because GLP-1 medicines are processed by the body over weeks and require titration, they must be hard on the liver in the way some older medications are. That worry is understandable, and it's worth letting go of gently, because the current evidence points the other way for most people.

Semaglutide does not carry the same hepatotoxicity concerns associated with certain oral medicines metabolised heavily by the liver. It is cleared through protein catabolism pathways rather than traditional hepatic metabolism, which is part of why it does not interact with liver function in the way people fear. What the trials actually show is that in people with excess weight and fatty liver disease, semaglutide tends to reduce liver fat accumulation, ease inflammation, and in some cases improve fibrosis scores. The MHRA's announcement of the MASH indication on 3 July 2026 makes this more than a theoretical finding, it is now a licensed therapeutic effect. That is a meaningful distinction from a medicine that merely avoids harming the liver.

For people with healthy livers, the picture is simpler still: no pattern of liver injury has emerged from the large Wegovy trial programme, and routine liver-function testing is not a standard monitoring requirement under current UK guidance for most patients.

What actually happens to liver enzymes on Wegovy

Some people do see their liver enzyme readings (particularly ALT) shift in the early weeks of treatment. This tends to reflect the metabolic changes happening across the whole body as weight begins to fall and insulin sensitivity improves, rather than direct liver toxicity.

Rapid weight loss by any means can temporarily mobilise stored liver fat faster than the liver can process it, which is why the gradual titration schedule built into Wegovy's licensed dosing matters. Starting at 0.25mg and stepping up over months is not arbitrary, it allows the body to adjust steadily. If you want to understand how liver enzyme levels specifically change during treatment, our page on Wegovy and liver enzymes covers that in more detail.

People who have a confirmed diagnosis of significant liver disease (particularly cirrhosis or conditions affecting bile flow) should discuss their situation explicitly with a specialist before starting. The prescriber reviewing your consultation will look at your medical history as a whole; it is not a decision made from a BMI number alone. For anyone uncertain about how Wegovy relates to liver function tests they have already had, that page addresses the specific question of what those results mean in context.

The 2026 MASH approval and what it means for liver disease

MASH (metabolic dysfunction-associated steatohepatitis) is a progressive form of fatty liver disease characterised by inflammation and scarring. It affects a significant proportion of people with obesity or type 2 diabetes, and until recently there were no licensed medicines that directly targeted it.

The MHRA's conditional approval of semaglutide (Wegovy) for MASH in adults with moderate-to-advanced fibrosis, confirmed on 3 July 2026, was based on trial data showing meaningful improvements in both liver inflammation and fibrosis scores compared with placebo. This is separate from Wegovy's weight-management licence, and it is worth being clear: nume prescribes Wegovy for weight management. If someone has a confirmed MASH diagnosis, the right clinician to lead their care is a hepatologist or gastroenterologist, not a weight-loss service. The two things can coexist, but the treatment plan needs specialist input.

You can read about the broader question of how semaglutide affects the liver (covering both the injectable and oral forms) for a wider view of the evidence. The NHS medicines page for semaglutide is also a reliable starting point for patient-level information about how this medicine is used and monitored in the UK.

Who to speak to, and when

If you have been told your liver enzymes are elevated, have a diagnosis of fatty liver disease, or are simply uncertain whether Wegovy is appropriate given your liver health, the right next step is a conversation with a clinician rather than an assumption in either direction.

At nume, a GPhC-registered Independent Prescriber reads every consultation personally, not software, not an algorithm. If your history suggests a question that needs specialist input, our prescribers will say so clearly. That kind of clinical judgement is exactly what a prescription process is for. Our clinical team can answer questions about medical suitability, and our FAQs cover many of the practical questions people have about starting treatment.

If you are also thinking about how Wegovy interacts with cardiovascular health alongside liver health, the page on Wegovy and the heart addresses the cardiovascular evidence separately. And if cost is a factor in your thinking, a straightforward overview of Wegovy pricing in the UK sets out what private treatment currently involves. When you are ready, you can speak to our prescribers through a free consultation, reviewed the same day, with no subscription and no hidden fees.